http://www.lsis.com/goto/r38/rss 2010-06-23T11:10:13+01:00 text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%97f%FE%12%7D%7E%7D DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/2ddbd5/pharmaceutical_ind) has announced the addition of the "Pharmaceutical Industry in China" report to their offering. Favorable economic conditions are expected to continue to boost the growth of the pharmaceutical industry in China. The health of the pharmaceutical industry has been improving continuously since 2000 and is expected to get even better. The Chinese pharmaceuticals market is forecast to become the world's fifth largest by 2010 - and the largest by 2050. There are still greater market access following China's entry into the World Trade Organization (WTO), multinational investors (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v38/%3B%97f%FF%12xz%7E Reuters - German drugmaker Stada aims to take part in consolidation of the generics sector and could use acquisitions in the medium term to complement the growth it generates itself, Chief Executive Hartmut Retzlaff said. text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%97f%FF%15uv%7D DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/ba2eb8/medicated_skin_car) has announced the addition of the "Medicated Skin Care in Germany" report to their offering. In 2009, medicated skin care benefited from the long and hot summer which was enjoyed across most parts of Germany. Remedies for heat-related problems such as topical antifungals and antiparasitics saw sales increase due to the favourable weather conditions. As a result, sales of medicated skin care in 2009 grew twice as fast as the review period average. The Medicated Skin Care Products in Germany report offers a comprehensive guide to the size and shape of the market at a national (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%97g%FB%13%7Cx%7B DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/df6d71/russia_pharmaceuti) has announced the addition of the "Russia Pharmaceuticals and Healthcare Report Q2 2010" report to their offering. Russia Pharmaceuticals and Healthcare Report Q2 2010 The Russia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Russia's pharmaceuticals and healthcare industry. The report expects the Russian pharmaceutical market to rebound from a difficult year in 2009 and return to (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%97g%FE%11zys NEW YORK-(BUSINESS WIRE)-Smart life science companies locate to Hessen, a leading economic growth engine in Europe. Hessen, with Frankfurt at its core, is the ideal base from which biotechnology and service companies can access a most dynamic market. While at BIO 2010, May 3-6, 2010, the Hessen Team will be meeting with companies interested in expanding to Germany/Europe to discuss the region s advantages and cost-free expert location advisory services. Representing Hessen at BIO 2010, will be Professor Dr. Theo Dingermann, Johann Wolfgang Goethe-University, Institute for Pharmaceutical Biology BioCenter in Frankfurt; Kristina L. Garcia, Managing Director, Hessen s U.S. Office for (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%97%60%FA%1C%7Ew%7B NEW YORK-(BUSINESS WIRE)-Smart life science companies locate to Hessen, a leading economic growth engine in Europe. Hessen, with Frankfurt at its core, is the ideal base from which biotechnology and service companies can access a most dynamic market. While at BIO 2010, May 3-6, 2010, the Hessen Team will be meeting with companies interested in expanding to Germany/Europe to discuss the region s advantages and cost-free expert location advisory services. Representing Hessen at BIO 2010, will be Professor Dr. Theo Dingermann, Johann Wolfgang Goethe-University, Institute for Pharmaceutical Biology BioCenter in Frankfurt; Kristina L. Garcia, Managing Director, Hessen s U.S. Office for (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%97%60%FF%1Cuv%7F DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/4cc3a7/discovery_stage_pa) has announced the addition of the "Discovery Stage Partnering Agreements in Biopharma" report to their offering. The Discovery Stage Partnering Agreements in Biopharma report provides a detailed understanding and analysis of how and why companies enter discovery stage licensing/business development and other forms of partnering arrangement. The focus of the report is on partnerships for discovery technologies and discovery stage compounds where partners have joined forces to exploit these early stage opportunities. This is the earliest stage of partnering undertaken by (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/goto/v38/%3B%97a%FB%1C%7Fx%7C NEW YORK, March 2 /PRNewswire/ - Reportlinker.com announces that a new market research report is available in its catalogue: Oncology Market Leaders Analyses and Outlook 2010-2025 http:/www.reportlinker.com/p0180093/Oncology-Market-Leaders-Analyses-and-Outlook-2010-2025.html Cancer treatment is a global healthcare priority, one with rising therapeutic and commercial importance. Over 20 million new cases of cancer are predicted in 2025, compared with 12 million in 2008 (WHO). Furthermore, anti-cancer drug sales exceeded $50bn worldwide in 2009. The oncology drug market has grown impressively, driven by rising disease prevalence, expanding patient populations and technological advances, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%97a%FC%16%7Ev%7B DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/47cfee/russia_pharmaceuti) has announced the addition of the "Russia Pharmaceuticals and Healthcare Report Q1 2010" report to their offering. Russia Pharmaceuticals and Healthcare Report Q1 2010 The Russian Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Russia's pharmaceuticals and healthcare industry. After a period of deep uncertainty, Russia's pharmaceutical market is surging with new investment projects (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%97b%F6%1C%7Bvr DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/cce6ba/pharmaceutical_com) has announced the addition of the "Pharmaceutical Companies Performance: Winers and Losers in a Recession-Hit Industry" report to their offering. Pharmaceutical Companies Performance: Winers and Losers in a Recession-Hit Industry While the ongoing recession has impacted the pharmaceutical industry's performance, some observers feel it has merely exacerbated many underlying problems. The number of blockbuster drugs which have lost patent protection have not been replaced by the same number of new products offering significant therapeutic advances, and the number coming off (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%97b%F6%1C%7Byz DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/99e1cf/the_world_generic) has announced the addition of the "The World Generic Market Report 2010" report to their offering. This new 2 volume, 680-page edition is packed with facts, figures, analysis and statistics, that provides the most thorough analysis available on generic markets, products and companies and the issues they face. Consolidation continues as US companies expand: Corporate consolidation continues to change the operating landscape, most notably the move by US company Mylan in its acquisition of Merck Generics and recent purchase of Arrow. These developments mark a more international (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%97b%FE%13yz%7B DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/40f723/serbia_pharmaceuti) has announced the addition of the "Serbia Pharmaceuticals and Healthcare Report Q1 2010" report to their offering. Serbia Pharmaceuticals and Healthcare Report Q1 2010 Serbia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Serbia's pharmaceuticals and healthcare industry. In the updated Business Environment Rating matrix for Q110, Serbia slipped from 9th to 12th position, out of the 20 (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/goto/v38/%3B%97b%FE%14zyy NEW YORK, Jan. 12 /PRNewswire/ - Reportlinker.com announces that a new market research report is available in its catalogue: Generic and Biogeneric Drugs for 15 Major Therapeutic Categories http:/www.reportlinker.com/p0170918/Generic-and-Biogeneric-Drugs-for-15-Major-Therapeutic-Categories .html This report reviews, analyzes and sizes the generic and biogeneric drug markets, particularly focusing on new biogeneric medicines. This report assesses the generic prescription market and maps the competitive landscape. The market forecast section sizes the market and discusses the five-year revenue projection to 2013. The market is segmented by key therapeutic applications, into major world (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96j%FA%15%7Fvx DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/fe5816/the_future_of_bios) has announced the addition of the "The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways" report to their offering. The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways Escalating Healthcare Expenditures Increase the Need for Low Cost Biosimilars This analysis has found that the proposals for the approval pathway of biosimilars, also called follow-on biologics (FOB) in the US, have the ability to shape the future of the biosimilars industry. The reduction of healthcare expenditures is (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/goto/v38/%3B%96j%FB%1Czv%7F NEW YORK, Dec. 2 /PRNewswire/ - Reportlinker.com announces that a new market research report is available in its catalogue: Pharmaceutical Contract Manufacturing - Global Market Trends http:/www.reportlinker.com/p0164248/Pharmaceutical-Contract-Manufacturing-Global-Market-Trends.html Global pharma industry faces numerous challenges in the form of increasing competition in generic markets, rising cost of new product development, declining research and development (R&D) productivity, shrinking average patent life, and mounting governmental pressure to reduce drug prices. Given the backdrop of such a competitive landscape, the decisive factors for growth and sustainability are faster new (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/goto/v38/%3B%96j%FB%1Dx%7C%7B NEW YORK, Dec. 15 /PRNewswire/ - Reportlinker.com announces that a new market research report is available in its catalogue: The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways http:/www.reportlinker.com/p0168103/The-Future-of -Biosimilars-Market-Forecasts-to-2015-Opportunity-Analysis-and-Regulatory-Pathways.html Summary The author has released its latest research "The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways". The report provides insights on the biosimilars market revenues and growth until 2015. Further, the distribution of revenues across key geographies such as the US, the top five (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96j%FC%10y%7Dr DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/6d074d/pharmaceutical_con) has announced the addition of the "Pharmaceutical Contract Manufacturing - Global Market Trends" report to their offering. Global pharma industry faces numerous challenges in the form of increasing competition in generic markets, rising cost of new product development, declining research and development (R&D) productivity, shrinking average patent life, and mounting governmental pressure to reduce drug prices. Given the backdrop of such a competitive landscape, the decisive factors for growth and sustainability are faster new drug development and cost containment with (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96j%FD%13%7Ezz DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/6539e0/russia_pharmaceuti) has announced the addition of the "Russia Pharmaceuticals and Healthcare Report Q4 2009" report to their offering. The Russia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Russia's pharmaceuticals and healthcare industry. This quarter BMI introduces 10-year forecasts for the Russian pharmaceutical markets, providing an opportunity to look beyond the current financial crisis and assess (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96k%F6%13%7D%7D%7F DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/c77b21/world_market_for_a) has announced the addition of the "World Market for Addiction Disorders, 2009-2016, The Future Therapies for Substance Dependence and Impulse Control" report to their offering. The report estimates that the current market for addiction disorders is valued at US$3.2 billion and this is forecast to increase 19% to US$3.8 billion by 2016. A comprehensive update of the 2005 edition Examines the market for addiction pharmacotherapies currently estimated at US$2 billion The substance dependence field is transforming into a high-growth market opportunity. Supported by the success (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96k%F9%10%7Dvz NEW YORK-(BUSINESS WIRE)-Reportlinker.com announces that a new market research report is available in its catalogue. Global Generics http:/www.reportlinker.com/p0119695/Global-Generics.html Global generics market was valued at US$106.12 billion in 2008, registering a growth of 12.56% over the previous year, which is five times that of patented drugs. Cygnus estimates that the global generics market will sustain a CAGR of 14% during the period, 2008-12. Patent expiries of blockbuster drugs and increasing healthcare expenditure will continue to drive the growth of the industry. The major generic firms will become more dominant with further acquisitions in future. Scope of the Report: i. (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96k%F9%11zw%7F NEW YORK-(BUSINESS WIRE)-Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds World Generics Market 2009-2024 http:/www.reportlinker.com/p0151196/Reportlinker-Adds-World-Generics-Market-2009-2024.html Impending patent expiries, increasing competition and changes in legislation: where will generics go from 2009 onwards? Our new report - World Generics Market 2009-2024 - explains the opportunities and challenges there The generic pharmaceuticals sector has been expanding strongly in recent years as the need for cheaper medicines worldwide has increased. The next five years from 2009 will see more leading drugs going off patent, thus (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96k%FB%10%7F%7E%7F DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/0b4072/serbia_pharmaceuti) has announced the addition of the "Serbia Pharmaceuticals and Healthcare Report Q4 2009" report to their offering. This Serbia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Serbia's pharmaceuticals and healthcare industry In the Q409 Business Environment Rating (BER) matrix, Serbia continued to improve its placement, and is now found in 9th position, out of the 20 key markets surveyed (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96k%FB%14u%7D%7C DUBLIN-(BUSINESS WIRE)-Research and Markets(http:/www.researchandmarkets.com/research/85cb7f/biosimilars_2009) has announced the addition of the "Biosimilars (2009 - 2014)" report to their offering. The impending expiry of several patented blockbuster biopharmaceuticals and the increasing demand from patients, insurers, and government agencies to reduce drug costs have created numerous opportunities in the global biosimilars market. The global biosimilars market is expected to be worth US$19.4 billion by 2014, growing at a CAGR of 89.1% from 2009 to 2014. The biosimilars market is segmented into peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96k%FB%14u%7D%7D DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/828189/generics_growth_st) has announced the addition of the "Generics Growth Strategies: Cost Containment and M&A Shape the Global Generics Industry" report to their offering. The last three years has seen several major shifts in generics company strategies. From 2006 to 2008 a period of high M&A activity was seen as many companies sought to expand geographically and create the scale required to compete with large pharmaceutical companies. Since the global financial crisis the level of deals has declined due to the implications of restricted debt markets and the need to reduce company debt. The (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96k%FC%1D%7F%7C%7C NEW YORK-(BUSINESS WIRE)-Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Biosimilars (2009 - 2014) http:/www.reportlinker.com/p0150471/Reportlinker-Adds-Biosimilars-(2009-2014).html Report Description The impending expiry of several patented blockbuster biopharmaceuticals and the increasing demand from patients, insurers, and government agencies to reduce drug costs have created numerous opportunities in the global biosimilars market. The global biosimilars market is expected to be worth US$19.4 billion by 2014, growing at a CAGR of 89.1% from 2009 to 2014. The biosimilars market is segmented into peptides, recombinant (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96k%FC%14%7B%7F%7C NEW YORK-(BUSINESS WIRE)-Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Generics Growth Strategies: Cost containment and M&A shape the global generics industry http:/www.reportlinker.com/p0148150/Reportlinker-Adds-Generics-Growth-Strategies-Cost-containment-and-MA-shape-the-global-generics-industry.html Executive Summary The last three years has seen several major shifts in generics company strategies. From 2006 to 2008 a period of high M&A activity was seen as many companies sought to expand geographically and create the scale required to compete with large pharmaceutical companies. Since the global financial crisis the (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96k%FC%14zxr NEW YORK-(BUSINESS WIRE)-Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds The Evolving Pharma M&A Landscape: Emerging trends and predicted post-blockbuster targets http:/www.reportlinker.com/p0148139/Reportlinker-Adds-The-Evolving-Pharma-MA-Landscape-Emerging-trends-and-predicted-post-blockbuster-targets.html Executive Summary Pharmaceutical market growth rates have halved inside the past five years, and will remain modest into the next decade. At the same time, new drug approval rates have slowed. With costs continuing to rise, the industrys margins are already being squeezed, but will come under growing pressure as payers (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96d%F8%14%7Eyy NEW YORK-(BUSINESS WIRE)-Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds World Market for Biosimilars and the Potential for US Follow-on Biologics, The http:/www.reportlinker.com/p0137883/Reportlinker-Adds-World-Market-for-Biosimilars-and-the-Potential-for-US-Follow-on-Biologics-The.html Biosimilars, or generic biologic drugs, are marketed around the world but still restricted in the U.S. This may soon change, and Kalorama Information has released this timely study of the market in Europe and other areas in the world and the possibility of a U.S. Market in the near future. As part of its research, this Kalormaa Information (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96d%FC%10yv%7E DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/83b1b1/russia_pharmaceuti) has announced the addition of the "Russia Pharmaceuticals and Healthcare Report Q3 2009" report to their offering. The Russia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Russia's pharmaceuticals and healthcare industry. Russia's overall macroeconomic situation has stabilised markedly since the end of Q109 - most notably as the ruble's managed devaluation earlier in the year did not (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v38/%3B%96d%FC%17xy%7E Reuters - German generic-drugs maker Stada Arzneimittel said its finance chief would leave immediately, without giving a reason, and also reported a 20 percent drop in first-half adjusted net income. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v38/%3B%96e%F7%16t%7Fz Alendronic acid, a frequently applied compound for the treatment of different forms of diseases of bone metabolism, is a strong acid with a high solubility in water. In connection with the oral administration this exhibits a potential health risk for the upper gastrointestinal tract. The in vitro release of tablets containing alendronic acid of different brands (Stada(R), ratiopharm(R), interpharm(R), Fosamax(R) was determined by dissolution tests for the time period required for oral intake. The effect of rotation speed, temperature, and solvent volume on the release rate of alendronic acid was determined for the used dissolution apparatus. Analysis of alendronic acid was performed by a (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96e%FA%10%7Fx%7D DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/13ff68/special_report_un) has announced the addition of Decision Resources, Inc.'s new report "Special Report: Understanding Treatment Dynamics and Needs in Juvenile Idiopathic Arthritis" to their offering. Although interviewed thought leaders acknowledge that available biological therapies have greatly improved treatment of juvenile idiopathic arthritis (JIA) the most common rheumatic disease in childrenthey do not hesitate to point out unmet needs and remaining drug development opportunities in this field. When current treatments fail, severe disability and even death can result. The heterogeneous (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96e%FB%10t%7D%7B DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/4f2719/germany_pharmaceut) has announced the addition of the "Germany Pharmaceuticals and Healthcare Report Q3 2009" report to their offering. Germany Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Germany's pharmaceutical and healthcare industry. Germany's drug market expenditure reached a value of EUR40.6bn (US$59.7bn) in 2008. The value of the country's pharmaceutical market is forecast to reach EUR48.6bn (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96e%FF%13%7Dz%7C DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/cffc40/cipla_generics_com) has announced the addition of the "Cipla Generics Company Intelligence Report" company profile to their offering. Cipla was founded in Bombay in 1935, and released its first products in 1937. The company first gained US FDA approval for its bulk drug facilities in 1985. The company has seven facilities in India and is planning an eighth. Sales for fiscal 2008 amounted to Rs43.4 billion, crossing the US$1 billion threshold for the first time. Revenues to Africa accounted for 34% of the total. Revenues attributed to Cipla's sales of tablets and capsules were worth Rs23.1 (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96f%F7%1C%7Bz%7D NEW YORK-(BUSINESS WIRE)-Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Biosimilars and Follow-On Biologics Report: The Global Outlook 2009-2024 http:/www.reportlinker.com/p0120955/Reportlinker-Adds-Biosimilars-and-Follow-On-Biologics-Report-The-Global-Outlook-2009-2024.html There is great demand for lower-cost biological drugs: commercial and regulatory developments will make biosimilars and follow-on biologics a success our new report explains how Revenues for biologic drugs reached approximately $125bn in 2008. Patents on most current biologics have expired or will expire during the period 2009 to 2024. In addition, there (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96f%F7%1D%7D%7Cy DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/9d6adc/the_top_10_biosimi) has announced the addition of the "The Top 10 Biosimilar Players: Positioning, Performance and SWOT Analyses" report to their offering. An estimated $25bn worth of biologics will lose patent protection by 2016, creating a significant market opportunity for biosimilars. Monoclonal Antibodies (mAb) such as Herceptin and Rituxan/Mabthera are among a number of major biologics going off-patent during this period. Teva is the third largest company in the global biosimilars market, with a share of 2.1% based on sales of $12m in 1H 2008. The company is investing in R&D and (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96f%F7%14%7Cys NEW YORK-(BUSINESS WIRE)-Reportlinker.com announces that a new market research report is available in its catalogue. The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses http:/www.reportlinker.com/p0119737/The-Top-10-Biosimilar-Players-Positioning-performance-and-SWOT-analyses.html Biologics continue to outperform the global pharma market, driven by premium priced therapies for conditions that cannot be managed by conventional drugs. The rapid penetration of novel biologics and the gradual expiry of their patents will create significant market opportunities for biosimilars developers through to 2016. In the short term, biosimilar market growth will be driven by drug (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96f%F8%16%7B%7F%7C DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/991700/global_generics_in) has announced the addition of the "Global Generics Industry Report" report to their offering. The global generics market was valued at US$106.12 billion in 2008, registering a growth of 12.56% over the previous year, which is five times that of patented drugs. Cygnus estimates that the global generics market will sustain a CAGR of 14% during the period, 2008-12. Patent expiries of blockbuster drugs and increasing healthcare expenditure will continue to drive the growth of the industry. The major generic firms will become more dominant with further acquisitions in the future. (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96g%F7%15%7Fw%7E DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/15aa7f/world_generic_mark) has announced the addition of the "World Generic Market Report 2009" report to their offering. This new 2 volume, 714-page edition is packed with facts, figures, analysis and statistics, that provides the most thorough analysis available on generic markets, products and companies and the issues they face. The changing face of the generics industry: Corporate consolidation continues to change the operating landscape, most notably with the acquisition of Barr Pharma by Teva which has created by far the largest generics company and a major player on the global pharmaceutical (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96g%F8%1Ct%7Cr DUBLIN, Ireland-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/e5e18d/russia_pharmaceuti) has announced the addition of the "Russia Pharmaceuticals and Healthcare Report Q1 2009" report to their offering. The global financial crisis and falling oil prices will have a substantial impact on the Russian pharmaceutical market in 2009. The question is whether the present weakening of the rouble, dearth in lending and broader crisis of confidence will trigger a full-blown meltdown in the marketplace. In its new five-year forecast through 2013, forecast are cautious but nonetheless anticipates continued growth. 2009 will see a major slowdown, with market growth (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96g%F8%10%7Bvz DUBLIN, Ireland-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/df26ef/generichandbook) has announced the addition of the "GenericHandbook - A Guide to the Generic Drug Industry in the US" report to their offering. Coverage includes sections: - Products / Market - Regulatory - Top company profiles TOPICS COVERED INCLUDE: - Impact of the NEW Obama Administration on the Generic Drug Industry - Analysis of recent Patent Litigation effecting the Generic Drug Industry - Medicare and Medicaid pricing policies - Intellectual property status and expirations dates for all branded drug products - Emerging competition in India,China and Eastern Europe - Recent (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v38/%3B%96g%F8%14%7E%7Ey WESTLAKE, Texas, Feb. 4, 2009 (GLOBE NEWSWIRE) - MiddleBrook Pharmaceuticals, Inc. (Nasdaq:MBRK), a pharmaceutical company committed to developing anti-infective products that fulfill unmet medical needs, today announced that it has retained Almac Pharma Services(r) to provide packaging services for physician samples of MOXATAG (amoxicillin extended-release) Tablets, 775 mg. Almac Pharma Services(r) will work closely with MiddleBrook's chosen commercial manufacturer, STADA Production Ireland(r). text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96g%F9%14y%7B%7C DUBLIN, Ireland-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/ad7963/copromotion_and_c) has announced the addition of the "Co-promotion and Co-marketing Agreements in Biopharma, 2nd Edition" report to their offering. The Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the world's leading biopharma companies. This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96g%FA%1Dz%7F%7E DUBLIN, Ireland-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/5768c8/serbia_pharmaceuti) has announced the addition of the "Serbia Pharmaceuticals and Healthcare Report Q1 2009" report to their offering. This Serbia Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Serbia's pharmaceuticals and healthcare industry. The value of the Serbian pharmaceutical market was estimated at US$1.17bn in 2008, with the figure likely to top US$1.7bn by the end of 2013. Main therapeutic areas for prescription products are cardiovascular drugs and antibiotics, with the latter being illustrative of an emerging market. In (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96g%FA%16t%7D%7D DUBLIN, Ireland-(BUSINESS WIRE)-Research and Markets(http:/www.researchandmarkets.com/research/8550ad/the_pharmaceutical) has announced the addition of the "The Pharmaceutical Market: Germany" report to their offering. Germany is the third largest pharmaceutical market in the world and the largest in Europe. Although the domestic consumption of pharmaceuticals is being constrained by government policy, the export market continues to expand. Germany also has the largest generic market in Europe. Recent EIU data suggests that German economic growth is minimal, which is also slowing growth in other European countries. Although domestic growth may be sluggish, exports are continuing to (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96g%FD%17%7E%7E%7E NEW YORK-(BUSINESS WIRE)-Reportlinker.com announces that a new market research report related to the Pharmaceutical industry is available in its catalogue. World Generics Market, 2008-2013 http:/www.reportlinker.com/p099471/World-Generics-Market-2008-2013.html The generics market remains a major growth area in the global healthcare market. That growth has been partly driven by cost-containment in several national healthcare sectors, with governments seeking to promote the use of generic products over higher-priced originator products. The global generic pharmaceuticals market was worth over $100bn in 2007, with market growth noticeably higher that that of the overall pharmaceutical (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96g%FE%12xw%7C DUBLIN, Ireland-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/fe6635/russia_pharmaceuti) has announced the addition of the "Russia Pharmaceuticals and Healthcare Report Q4 2008" report to their offering. Our Russia Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Russia's pharmaceuticals and healthcare industry. Despite a bruising a few months for the Russian economy as a whole, BMI broadly maintains an optimistic growth outlook for the Russian pharmaceutical market for the period 2008 to 2012. We have lowered our US dollar growth rate estimates based on updated exchange-rate forecasts with the (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96g%FF%1Dt%7C%7B NEW YORK-(BUSINESS WIRE)-Reportlinker.com announces that a new market research report related to the Diagnostic equipment industry is available in its catalogue. World Growth Factors (Blood And Tissue) Market http:/www.reportlinker.com/p098265/World-Growth-Factors-(Blood-And-Tissue)-Market.html This report analyzes the worldwide markets for Growth Factors (Blood And Tissue) in Millions of US$. The major product segments analyzed are Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, & Interleukins), and Tissue Growth Factors. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96%60%F7%15%7D%7B%7C DUBLIN, Ireland-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/865c5f/meeting_the_challe) has announced the addition of Decision Resources, Inc.'s new report "Meeting the Challenges of Manufacturing Biosimilars" to their offering. Branded biologics have, until recently, been immune to generics competition; however, the approval of biosimilars in Europe heralds a changing landscape. Legislation enabling the approval of biosimilars is stalled in the U.S. Congress but could pass in 2009, and President-elect Obama supports establishing a biosimilars regulatory framework. Complex manufacturing issues pose some of the most significant challenges to companies (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v38/%3B%96%60%F8%1C%7Bwr DUBLIN, Ireland-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/c2c257/vietnam_pharmaceut) has announced the addition of the "Vietnam Pharmaceuticals and Healthcare Report Q4 2008" report to their offering. Vietnam Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Vietnam's pharmaceuticals and healthcare industry. Despite still being ranked 12th out of 14 key regional countries in our Business Environment Rankings for Q408, the Vietnamese pharmaceutical market is expected to overtake its neighbours in the coming years. Key reasons for this include the expected double-digit growth over the next five years, (…)